相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
已完成
3
50.0%
Unknown
3
50.0%
暂无批准数据
- BioElectronics Corporation has doubled its facility space following a Fulfillment Services and Distribution Control Agreement with Electrome Corporation to support the U.S. direct-to-consumer launch of ActiPatch. - The expanded facility will provide inventory receiving, storage, order processing, packing, shipping coordination, and returns management for Electrome's planned DTC sales channel. - The new fulfillment center will also support anticipated orders for RecoveryRx, BioElectronics' FDA-cleared prescription medical device for postoperative and musculoskeletal pain. - The agreement creates a service-based revenue stream for BioElectronics through monthly storage fees, pick-and-pack fees, and other fulfillment-related charges.
• A recent study found that pulsed shortwave therapy (PSWT) did not significantly reduce pain scores in patients after common surgeries. • The research also indicated that PSWT did not lead to a statistically significant decrease in opioid consumption during the initial postoperative week. • The study's authors suggest that these findings need replication in future trials before definitive conclusions can be made about PSWT's efficacy for pain control. • Despite prior FDA clearance for PSWT devices, this trial highlights the ongoing need for robust evidence supporting their clinical use for pain management.
